Key facts
- Hyalex Orthopaedics’s last known valuation is $68.9M.
- It has raised $47.9M across 2 recorded rounds; the latest was Early Stage VC ($14.9M) in Sep 2024.
- Notable investors include MedTech Innovator, Canaan Partners, Johnson & Johnson JJDC, Osage University Partners, Treo Ventures — 7 tracked in total.
- Hyalex Orthopaedics has filed 4 Form Ds with the SEC since 2017, most recently Oct 2024 ($14.9M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Hyalex Orthopaedics
Funding rounds
2 roundsAbout Hyalex Orthopaedics
Developer of a biomimetic material designed to simulate cartilages for diseased and damaged joints. The company's synthetic material can maintain low friction and wear under high loads encountered in human joints, enabling doctors to replace arthritic cartilage while sparing healthy bone.
- Sector
- Healthcare
- HQ
- Lexington, MA, United States
- Founded
- 2016
- Employees
- 24
- Website
- hyalex.com/
- Ownership
- Privately Held (backing)
Hyalex Orthopaedics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hyalex Orthopaedics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hyalex Orthopaedics in its N-PORT filings yet. We sweep new filings monthly.